Literature DB >> 25053820

Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer.

Christopher L Daige1, Jason F Wiggins1, Leslie Priddy1, Terri Nelligan-Davis1, Jane Zhao1, David Brown2.   

Abstract

miR34a is a tumor-suppressor miRNA that functions within the p53 pathway to regulate cell-cycle progression and apoptosis. With apparent roles in metastasis and cancer stem cell development, miR34a provides an interesting opportunity for therapeutic development. A mimic of miR34a was complexed with an amphoteric liposomal formulation and tested in two different orthotopic models of liver cancer. Systemic dosing of the formulated miR34a mimic increased the levels of miR34a in tumors by approximately 1,000-fold and caused statistically significant decreases in the mRNA levels of several miR34a targets. The administration of the formulated miR34a mimic caused significant tumor growth inhibition in both models of liver cancer, and tumor regression was observed in more than one third of the animals. The antitumor activity was observed in the absence of any immunostimulatory effects or dose-limiting toxicities. Accumulation of the formulated miR34a mimic was also noted in the spleen, lung, and kidney, suggesting the potential for therapeutic use in other cancers. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25053820     DOI: 10.1158/1535-7163.MCT-14-0209

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  53 in total

Review 1.  Epigenetic regulation of peroxiredoxins: Implications in the pathogenesis of cancer.

Authors:  Suet-Hui Ow; Pei-Jou Chua; Boon-Huat Bay
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-04

Review 2.  miRNA nanotherapeutics for cancer.

Authors:  Aditya Ganju; Sheema Khan; Bilal B Hafeez; Stephen W Behrman; Murali M Yallapu; Subhash C Chauhan; Meena Jaggi
Journal:  Drug Discov Today       Date:  2016-11-01       Impact factor: 7.851

3.  Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR2 and miR-34a.

Authors:  Jianguo Bai; Jianfei Wu; Ruifeng Tang; Chao Sun; Junwei Ji; Zhaolin Yin; Guangjun Ma; Wei Yang
Journal:  Invest New Drugs       Date:  2019-04-11       Impact factor: 3.850

4.  Layer-by-layer assembled PLGA nanoparticles carrying miR-34a cargo inhibit the proliferation and cell cycle progression of triple-negative breast cancer cells.

Authors:  Chintan H Kapadia; Stephen A Ioele; Emily S Day
Journal:  J Biomed Mater Res A       Date:  2019-11-26       Impact factor: 4.396

5.  Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model.

Authors:  Kejin Zhou; Liem H Nguyen; Jason B Miller; Yunfeng Yan; Petra Kos; Hu Xiong; Lin Li; Jing Hao; Jonathan T Minnig; Hao Zhu; Daniel J Siegwart
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-04       Impact factor: 11.205

Review 6.  Non-viral based miR delivery and recent developments.

Authors:  Annalise Elizabeth Labatut; George Mattheolabakis
Journal:  Eur J Pharm Biopharm       Date:  2018-04-19       Impact factor: 5.571

Review 7.  MicroRNAs in mucosal inflammation.

Authors:  Viola Neudecker; Xiaoyi Yuan; Jessica L Bowser; Holger K Eltzschig
Journal:  J Mol Med (Berl)       Date:  2017-07-20       Impact factor: 4.599

Review 8.  Knocking down disease: a progress report on siRNA therapeutics.

Authors:  Anders Wittrup; Judy Lieberman
Journal:  Nat Rev Genet       Date:  2015-09       Impact factor: 53.242

Review 9.  The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas.

Authors:  Brian D Adams; Christine Parsons; Frank J Slack
Journal:  Expert Opin Ther Targets       Date:  2015-12-11       Impact factor: 6.902

Review 10.  Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment.

Authors:  Worapol Ngamcherdtrakul; David J Castro; Shenda Gu; Jingga Morry; Moataz Reda; Joe W Gray; Wassana Yantasee
Journal:  Cancer Treat Rev       Date:  2016-02-22       Impact factor: 12.111

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.